Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
The Efficacy and Safety of Thymosin-alpha 1 Used for Adjuvant Treatment After Radical Resection of High-risk Stage II and Stage III Colorectal Cancer
Fudan University
2,500 participants
Apr 1, 2021
INTERVENTIONAL
Conditions
Summary
For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and stage III colorectal cancer after radical resection.
Eligibility
Inclusion Criteria4
- Colorectal cancer receiving radical resection
- Pathologically diagnosed with high-risk stage II or stage III
- Eastern Cooperative Oncology Group performance status of 0-2
- Adequate hepatic, renal, and hematologic function
Exclusion Criteria2
- Had previously taken any immune-promoting drugs
- Pregnancy or lactation
Interventions
Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05086614